Sullivan doctor gives health tips for men during Men's Health Month
Kilby Osborn is a physician for Sullivan County Community Hospital, and he said some health issues men should for are diseases like testicular or colon cancer.
He added that if something feels off, it probably is and men should get it checked out. He suggests everyone should get physicals regularly.
'Men, women, kids, you should all be getting physicals once a year. That's a good rule of thumb. You go in, you get checked out at the doctor once a year. You have labs done once a year. We can check your vital organs. We can check your liver. We can check your kidneys. We can check your blood sugar. We can sometimes find things that you might not even notice,' said Osborn.
He also emphasized the importance of catching health issues early so they're easier to treat.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
U.S. telehealth upstart plans to sell generic Ozempic in Canada as patent due to lapse
U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic semaglutide, the anti-diabetic medication used for the treatment of type 2 diabetes that is growing popularity as an anti-obesity medication. 'Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,' Hims & Hers chief executive Andrew Dudum said in a release announcing the company's plan. The opportunity for Hims and Hers comes as Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, Ozempic and Wegovy, after apparently failing to pay a small fee to maintain the patent. According to the Canadian Patent Database, Novo Nordisk was first issued the patent in 2013 but it is now 'expired and beyond the period of reversal.' A report by Science said the pharma company last paid the annual maintenance fee on 2018, which at the time was $250. Meanwhile, it will hold the patent in the United States until at least 2032. At the moment, there is still no generic version of semaglutide on the market that has been approved by Health Canada. In a press release, Hims and Hers said almost two-thirds of adults in Canada are overweight or living with obesity. Branded semaglutide with no surrounding clinical support currently costs more than $200 a month in Canada. It said the price for generic semaglutide is expected to be available at a significant discount to the branded versions, with the prices expected to lower over time. WeightWatchers files for bankruptcy after growth in weight loss drugs How Novo Nordisk CEO Lars Fruergaard Jørgensen rewrote the weight-loss game Hims and Hers stock traded up as much as 4.1 per cent after the company announced its plans to expand into Canada on Wednesday morning, but pared some of those gains by midday. The company had recently closed its acquisition of ZAVA, a digital health platform in Europe. • Email: dpaglinawan@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 hours ago
- Business Wire
Hims & Hers Announces Planned 2026 Expansion to Canada,
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering digital health platform in Europe. Almost two thirds of adults in Canada are overweight or living with obesity, yet access to proven treatments remains limited due to high costs and availability. With branded semaglutide often priced out of reach, the introduction of generics marks a pivotal moment for access to care. Hims & Hers plans to offer access to lower-cost treatment options through its digital platform, paired with 24/7 access to licensed providers and personalized, clinically backed care plans. In Canada, branded semaglutide with no surrounding clinical support currently costs more than C$200 a month. The price for generic semaglutide is expected to be available at a significant discount to the branded versions, with the prices expected to lower over time. 'Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,' said Andrew Dudum, co-founder and CEO of Hims & Hers. 'As generic semaglutide becomes available for the first time globally, we're focused on making it truly accessible, by combining affordability with trusted, personalized care at scale.' This moment represents a significant opportunity for Hims & Hers to accelerate its mission of broadening access to healthcare. By pairing the arrival of generics with a platform designed to scale, affordability, and clinical integrity, the company is positioned to meet growing demand with a better model of care, one that gives the patient real choice and puts providers in the lead. "Our planned expansion into Canada proves our commitment to bringing modern, effective care to those who need it most," said David Meinertz, GM International at Hims & Hers. "Despite North America being the largest GLP-1 market, many still lack crucial access. Making affordable, holistic obesity treatment accessible has the potential to help strengthen the local healthcare system and unlock the potential for millions of Canadians to live healthier, more fulfilling lives.' With ZAVA now part of Hims & Hers, the company is scaling care across markets where its comprehensive offerings can meet consumer needs. The plans for Canada entry reflect continued progress on a clear growth roadmap, leveraging both organic growth and strategic investments to expand category leadership and global reach. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and About ZAVA ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people's hands 24/7. Rated 'outstanding' for leadership by the UK Care Quality Commission, ZAVA combines medical rigour with a friction-free digital experience. ZAVA's comprehensive service portfolio spans weight management, women's and men's health, sexual health, general medicine and skin & hair care - helping people tackle both everyday and sensitive conditions quickly, discreetly and safely. Cautionary Note Regarding Forward-Looking Statements Except for historical information, certain statements in this press release, including statements regarding the effects of entering into the acquisition described above, the timing and effects of our plans to expand into Canada, our expectations regarding our planned expansion into Canada, our expectations regarding integration of the ZAVA acquisition, our future performance, anticipated customer demand and the expected size of the total addressable Canadian market, the expected timing of availability of generic semaglutide, the ability to scale our business, the solutions accessible on our platform, our future operational capabilities, our long-term strategy, and the underlying assumptions with respect to the foregoing, are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, our legal and regulatory environment, macroeconomic and geopolitical factors, and those factors described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the 'Commission'). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.
Yahoo
7 hours ago
- Yahoo
Community Health Systems, Inc. (CYH) Sells Its 80% Stake in Cedar Park Health System to Ascension Health
Community Health Systems, Inc. (NYSE:) is one of the . Community Health Systems, Inc. (NYSE:CYH) completed the sale of its 80% interest in Cedar Park Health System to Ascension Health. The $436 million cash transaction marks a significant divestiture and is expected to help the company streamline its operations and strengthen its liquidity amid ongoing financial restructuring plans. The sale took place on June 30, 2025. A healthcare provider holding an MRI scan of a patient with a traumatic brain injury. Despite the weak financial health of Community Health Systems, Inc. (NYSE:CYH), analysts remain cautiously optimistic. However, the $6 price target set by the analysts reflects optimism toward the company's asset monetization strategy and shareholder-support changes. Meanwhile, technical indicators show a mixed sentiment, with bearish momentum and valuation concerns weighing on the bullish outlooks. Community Health Systems, Inc. (NYSE:CYH) runs general acute care hospitals with a broad network of outpatient facilities across the U.S. The company offers a wide range of surgical, diagnostic, and virtual care services. It is one of the best stocks to buy. While we acknowledge the potential of CYH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 7 Best Future Food Stocks to Buy According to Analysts and 10 Best Marketing Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
